SCHEMBL1046937

SCHEMBL1046937

O=C(O)c1ccc(CNS(=O)(=O)c2ccc(F)cc2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 1/20 0.69
TSHR P16473 1/20 0.68
CYP2C19 P33261 3/20 0.66
CYP1A2 P05177 2/20 0.66
CYP2C9 P11712 2/20 0.66
POLB P06746 1/20 0.66
HPGD P15428 1/20 0.66
CA1 P00915 1/20 0.66
CA2 P00918 1/20 0.66
CA9 Q16790 1/20 0.66
MAPT P10636 1/20 0.60
CYP19A1 P11511 1/20 0.59
CYP3A4 P08684 1/20 0.58
GAA P10253 1/20 0.58
CYP2D6 P10635 1/20 0.58
KMT2A Q03164 1/20 0.58
PTPN1 P18031 1/20 0.57
PTPN6 P29350 1/20 0.57
PTPN11 Q06124 1/20 0.57
GPR55 Q9Y2T6 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL996398 0.86 KEAP1 (0.71) CXCR4TSHRCYP1A2HPGDCA1
SCHEMBL12530914 0.85 TSHR (0.72) TSHRCYP1A2POLBHPGDCA9
SCHEMBL1049418 0.85 TSHR (0.68) TSHRCA9MAPTCYP19A1KMT2A
SCHEMBL27726116 0.85 TSHR (0.72) TSHRCYP1A2HPGDCA1CA2
SCHEMBL1287408 0.85 TSHR (0.68) TSHRPOLBCYP19A1KMT2APTPN1
SCHEMBL1287354 0.84 POLB (0.65) CXCR4TSHRCYP2C19CYP1A2CYP2C9
SCHEMBL4663044 0.82 KEAP1 (0.76) CXCR4CYP2C19CYP1A2CYP2C9POLB
SCHEMBL6289448 0.82 CYP19A1 (0.78) CXCR4CYP1A2POLBCA1CA2
SCHEMBL19358855 0.82 CXCR4 (1.00) CXCR4TSHRCYP2C19CYP1A2CYP2C9
SCHEMBL1279547 0.81 TSHR (1.00) TSHRHPGDMAPTCYP19A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2456435-B1 HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE UNIV LELAND STANFORD JUNIOR (US) 2015-06-24 EP disclosed
US-20120225862-A1 HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE AUCKLAND UNIVSERVICES LIMITED (NZ) 2012-09-06 US disclosed
EP-2456435-A1 HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE The Board of Trustees of The Leland Stanford Junior University (US) 2012-05-30 EP disclosed
WO-2011011514-A1 HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2011-01-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225862-A1 HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE BRDT, NISCH, PAICS CXCR4 3954/4885TSHR 3930/4885CYP2C19 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.